Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer
Status:
Active, not recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This research study is testing the safety and feasibility of delivering the 4 cycles of
'dose-dense' paclitaxel without the use of Neulasta (Pegfilgrastim) as a Granulocyte
Colony-stimulating Factor (G-CSF) support. The research study is for participants who have
early stage breast cancer and have been recommended to receive a standard chemotherapy
regimen, doxorubicin/cyclophosphamide (AC) plus Paclitaxel (T), in what is called a
"dose-dense" fashion to prevent recurrences.